In:
BMJ Case Reports, BMJ, Vol. 12, No. 8 ( 2019-08), p. e230396-
Abstract:
Diffuse melanosis cutis (DMC) is an extremely rare and late complication of metastatic melanoma (MM). It involves the progressive blue-grey discolouration of the skin and mucous membranes, occurring approximately 1 year after diagnosis of MM. The pathogenesis of DMC is unknown, although specific growth factors, such as alpha-melanocyte stimulating hormone, hepatocyte growth factor and endothelin-1, released by cancer cells, along with release of melanin precursors in the bloodstream and dermal MM micrometastases producing melanin have been attributed. Even with appropriate therapy, DMC seems to be a poor prognostic factor, with a mean survival time of 4–5 months. Here, we report a case of BRAF-mutated MM who presented with DMC. The patient underwent BRAF/MEK inhibition followed by anti-PDL1 therapy, yet passed away approximately 1 year after diagnosis.
Type of Medium:
Online Resource
ISSN:
1757-790X
DOI:
10.1136/bcr-2019-230396
Language:
English
Publisher:
BMJ
Publication Date:
2019
detail.hit.zdb_id:
2467301-8
Permalink